Developing new cancer drugs is expensive. Before a new cancer drug goes to trial it is developed for a year or two, and costs around $100 million. Also, 95% of cancer drugs fail in clinical trials meaning there are lots of misses before a hit. Berg, a biotech startup, wants to harness artificial intelligence to develop the next generation of cancer treatments. The company has created BPM 31510, the first cancer drug developed by artificial intelligence being tested in clinical studies. When cancer spreads mitochondria that usually tell damaged cells to die go crazy, and spread. BPM 31510 focuses on the mitochondria, and tries to restore a normal cell’s dying process. Though BPM 31510 is still in early trial stages, it could hint at how future drugs will be developed.
The next frontier in medicine: drugs designed by artificial intelligence
More of Today's Solutions
Attention lazy gardeners! Why doing less can boost butterfly populations in y...
A recent scientific study published in the journal Science of the Total Environment demonstrates that a small change in lawn maintenance habits can have ...
Read MoreCoffee vs. tea: which caffeine source reigns supreme for health and vitality?
For many people, coffee is more than simply a morning habit; it's an integral component of their daily lives. But is this really the ...
Read MorePakistan’s Billion Tree project is bringing the bees and honey back
In 2018, Pakistan’s Prime Minister Imran Khan announced the Billion Tree project, a lofty country-wide effort to plant 10 billion trees over a 5-year ...
Read More7 Reasons why your next vacation should be a road trip
In these uncertain times, your dream vacation to a tropical island or a bustling foreign city may have been put on hold—but that doesn’t ...
Read More
